Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Sarah Faiz; Jonathan Giovannelli; Céline Podevin; Marie Jachiet; Jean-David Bouaziz; Ziad Reguiai; Audrey Nosbaum; Audrey Lasek; Marie-Christine Ferrier le Bouedec; Aurélie Du Thanh; Nadia Raison-Peyron; Florence Tetart; Anne-Bénédicte Duval-Modeste; Laurent Misery; François Aubin; Anne Dompmartin; Cécile Morice; Catherine Droitcourt; Angèle Soria; Jean-Philippe Arnault; Juliette Delaunay; Emmanuel Mahé; Marie-Aleth Richard; Amélie Schoeffler; Jean-Philippe Lacour; Edouard Begon; Amélie Walter-Lepage; Anne-Sophie Dillies; Sandrine Rappelle-Duruy; Stéphane Barete; Nathalia Bellon; Nathalie Bénéton; Aude Valois; Sébastien Barbarot; Julien Sénéchal; Delphine Staumont-Sallé; Groupe de Recherche sur l'Eczéma aTopique (GREAT), France

doi:10.1016/j.jaad.2019.02.053

Retour

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Article de revue

Avec comité de lecture

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Sarah Faiz, Jonathan Giovannelli, Céline Podevin, Marie Jachiet, Jean-David Bouaziz, Ziad Reguiai, Audrey Nosbaum, Audrey Lasek, Marie-Christine Ferrier le Bouedec, Aurélie Du Thanh, …

Journal of the American Academy of Dermatology, Vol.81(1), pp.143-151

01/07/2019

DOI: https://doi.org/10.1016/j.jaad.2019.02.053

PMID: 30825533

Résumé

adults

atopic dermatitis

biotherapy

conjunctivitis

dupilumab

eosinophilia

Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. No control group, missing data. This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
Créateurs - sans rôle: Sarah Faiz - Centre Hospitalier Universitaire de Lille
Jonathan Giovannelli - CHU de Lille, Service de dermatologie, F-59000 Lille, France
Céline Podevin - Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France
Marie Jachiet - Sorbonne Paris Cité
Jean-David Bouaziz - Sorbonne Paris Cité
Ziad Reguiai - Service de dermatologie, Polyclinique Courlancy, Reims, France
Audrey Nosbaum - Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite, University of Lyon, Lyon, France, CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France
Audrey Lasek - Service de dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, France
Marie-Christine Ferrier le Bouedec - Dermatology Department, University of Clermont-Ferrand, Clermont-Ferrand, France
Aurélie Du Thanh - Inserm
Nadia Raison-Peyron - Service de dermatologie, CHU Montpellier, Univ Montpellier, Montpellier, PCCI, INSERM, Univ Montpellier, Montpellier, France
Florence Tetart - Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France
Anne-Bénédicte Duval-Modeste - Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France
Laurent Misery - Department of Dermatology, University Hospital of Brest, Brest, France
François Aubin - Université de franche-comté
Anne Dompmartin - Department of Dermatology, Caen University Hospital Center, France
Cécile Morice - Department of Dermatology, Caen University Hospital Center, France
Catherine Droitcourt - Université de Rennes
Angèle Soria - Centre d'Immunologie et des Maladies Infectieuses
Jean-Philippe Arnault - Department of Dermatology, Amiens University Hospital, Amiens, France
Juliette Delaunay - Service de Dermatologie, CHU d'Angers site Larrey, Angers, France
Emmanuel Mahé - Department of Dermatology, Hôpital Victor Dupouy Argenteuil, Argenteuil, France
Marie-Aleth Richard - Aix-Marseille University, EA 3279, CEReSS- Health Service Research and Quality of Life Center, Dermatology Department, Timone Hospital, Assistance Publique Hôpitaux de Marseille, 13385, France
Amélie Schoeffler - Service de Dermatologie, Hôpital Bel Air, Centre Hospitalier Régional Metz-Thionville
Jean-Philippe Lacour - Service de Dermatologie, Hôpital l'Archet 2, CHU de Nice, France
Edouard Begon - Centre Hospitalier René-Dubos
Amélie Walter-Lepage - Service de Dermatologie, CHU La Miletrie, Poitiers, France
Anne-Sophie Dillies - Service de Dermatologie, Centre Hospitalier de Saint Quentin, France
Sandrine Rappelle-Duruy - Service de Dermatologie, Hôpital Joseph Imbert, Centre Hospitalier d'Arles, France
Stéphane Barete - Assistance Publique – Hôpitaux de Paris
Nathalia Bellon - Assistance Publique – Hôpitaux de Paris
Nathalie Bénéton - Service de Dermatologie, Centre Hospitalier de Le Mans, France
Aude Valois - Hôpital d'Instruction des Armées Sainte-Anne
Sébastien Barbarot - Service de Dermatologie, Hôtel Dieu, CHU de Nantes, France
Julien Sénéchal - Service de Dermatologie, Centre de Référence des Maladies Rares de la Peau, Hôpital Saint André, CHU de Bordeaux, France
Delphine Staumont-Sallé - Centre Hospitalier Universitaire de Lille
Groupe de Recherche sur l'Eczéma aTopique (GREAT), France
Détails de publication: Journal of the American Academy of Dermatology, Vol.81(1), pp.143-151
Éditeur: Elsevier Inc
Nombre de pages: 9
Note de subvention: Regenron
Identifiants: 99148729309311
Unité académique: Pathogenesis and Control of Chronic and Emerging Infections - PCCEI
Langue: English
Type de ressource: Journal article